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OBJECTIVE—Kinins mediate pathophysiological processes re-
lated to hypertension, pain, and inflammation through the acti-
vation of two G-protein–coupled receptors, named B1 and B2.
Although these peptides have been related to glucose homeosta-
sis, their effects on energy balance are still unknown.
RESEARCH DESIGN AND METHODS—Using genetic and
pharmacological strategies to abrogate the kinin B1 receptor in
different animal models of obesity, here we present evidence of
a novel role for kinins in the regulation of satiety and adiposity.
RESULTS—Kinin B1 receptor deficiency in mice (B1
/) re-
sulted in less fat content, hypoleptinemia, increased leptin sen-
sitivity, and robust protection against high-fat diet–induced
weight gain. Under high-fat diet, B1
/ also exhibited reduced
food intake, improved lipid oxidation, and increased energy
expenditure. Surprisingly, B1 receptor deficiency was not able to
decrease food intake and adiposity in obese mice lacking leptin
(ob/ob-B1
/). However, ob/ob-B1
/ mice were more responsive
to the effects of exogenous leptin on body weight and food
intake, suggesting that B1 receptors may be dependent on leptin
to display their metabolic roles. Finally, inhibition of weight gain
and food intake by B1 receptor ablation was pharmacologically
confirmed by long-term administration of the kinin B1 receptor
antagonist SSR240612 to mice under high-fat diet.
CONCLUSIONS—Our data suggest that kinin B1 receptors
participate in the regulation of the energy balance via a mecha-
nism that could involve the modulation of leptin sensitivity.
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A ccording to the World Health Organization, onebillion people worldwide are overweight, and atleast 300 million are clinically obese (www-.who.int). Besides the negative social stigma
carried by obese individuals, obesity can cause or exacer-
bate many health problems, such as type 2 diabetes,
cardiovascular diseases, and some cancers (1,2). Thus,
obesity is associated with increased mortality (3) and
accounts for up to 7.8% of the total health care expenses in
developed countries (4).
In 1994, Zhang et al. (5) contributed significantly to our
understanding of the endocrine mechanisms underlying
the regulation of body weight. The group identified a null
mutation in the ob gene that led mice to a phenotype of
severe obesity. The functions of the ob gene product, a
16-kDa cytokine called leptin, were further characterized
by several subsequent studies. Traditionally, it has been
shown that leptin acts in the arcuate nucleus of the
hypothalamus, inhibiting food intake and promoting en-
ergy expenditure (6). Lately, it has been shown that leptin
has a broad spectrum of action in many areas of the
central nervous system and peripheral organs. For in-
stance, it was shown that leptin prevents lipotoxicity in
liver, skeletal muscle, and pancreas by direct inhibition of
triglyceride formation and stimulation of free fatty acid
oxidation (7). Mice lacking leptin (ob/ob) show hyperpha-
gia, insulin resistance, hypothermia, reduced sympathetic
activation, and infertility, parameters that can be restored
after administration of exogenous leptin (6,8). Despite the
powerful metabolic actions of leptin, the therapeutic use
of this hormone was initially frustrated by observations
that plasma leptin levels were in fact elevated in obese
individuals (9), which indicated that obesity in humans
was accompanied by leptin resistance rather than hypo-
leptinemia. More recently, various mechanisms for leptin
resistance in obesity have been proposed. The two main
hypotheses are the saturation of the leptin transport
through the blood-brain barrier (10,11) and the failure of
components of the leptin receptor (Ob-Rb) signaling
pathway (12). It was shown, for example, that the
overexpression of the suppressor of cytokine signal-
ing-3 (SOCS3) caused leptin resistance in different ani-
mal models of obesity because it resulted in a strong
reduction of the Ob-Rb signal transduction (13). There-
fore, the identification of alternative factors that poten-
tiate leptin signaling may lead to useful therapeutic
approaches to treat obesity.
The kallikrein-kinin system represents a group of pro-
teins involved in the control of blood pressure, gastroin-
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testinal tract mobility, inflammation, and pain induction
(14,15). In this system, precursor proteins called kinino-
gens are cleaved by kallikreins to release kinins, which
can further be cleaved by carboxypeptidases to give rise to
des-Arg-kinins. The main active kinins are bradykinin and
its metabolite des-Arg9-bradykinin. Bradykinin and des-
Arg9-bradykinin use distinct G-protein–coupled receptors
to exert their effects. Whereas bradykinin interacts with
the B2 receptor subtype, des-Arg
9-bradykinin has higher
affinity for the B1 receptor (14). Kinin B2 receptors are
constitutively expressed in most tissues and exert most
functions attributed to the kallikrein-kinin system, includ-
ing vasodilation and salt excretion (14,16). Conversely, the
kinin B1 receptor is thought to be strongly induced by
inflammatory stimuli and to mediate processes of injury
and pain (14,15,17). Accordingly, kinin B1 receptor knock-
out mice (B1
/) are hypoalgesic, are less responsive to
lipopolysaccharide (LPS)-induced hypotension (18), and
present inhibition of neutrophil migration into inflamed
tissue (19).
Evidence that kinins induce insulin sensitivity in adipo-
cytes (20) and control insulin released by pancreatic cells
(21,22) indicates that the kallikrein-kinin system also
participates in metabolic processes. However, the physio-
logical relevance of this system to energy homeostasis and
the contributions of the kinin B1 receptor to these pro-
cesses are still not well understood. Recently, our group
showed that the B1 receptor mRNA is upregulated in the
white adipose tissue, liver, and hypothalamus of ob/ob
mice (23), suggesting for the first time a correlation
between obesity and the kinin B1 receptor. Furthermore,
we observed that des-Arg9-bradykinin administration in
mice is able to increase blood leptin levels (24). In the
present report, we examined the consequences of B1
receptor ablation on the etiopathology of obesity using
two animal models, the high-fat diet–induced obesity and
the obese ob/ob mice. In addition, we evaluated the effect
of pharmacological inhibition of B1 receptors on weight
gain and food intake of mice under high-fat diet. The
results of these studies strongly support a role for the
kinin B1 receptor in controlling body weight and fat
accumulation through a mechanism that may involve the
modulation of leptin signaling.
RESEARCH DESIGN AND METHODS
B1
/ mice (18) used in the experiments were originated from 10 generations’
backcrossing of an initially mixed genetic background (129/Sv and C57Bl/6)
with C57Bl/6 mice (Taconic, Germantown, NY). Therefore, C57Bl/6 animals
were used as their controls. The ob/ob-B1
/ strain was generated by cross-
breeding C57Bl/6 ob/ mice (The Jackson Laboratories, Bar Harbor, ME)
with B1
/ mice. Animals have been obtained from the Universidade Federal
de Sa˜o Paulo (Brazil), from the Max-Delbru¨ck-Center for Molecular Medicine
(Berlin-Buch, Germany), and from the Animal House (Toulouse, France). All
experiments reported have been conducted as stated in the National Institutes
of Health Guide for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, National Academy Press, Washington, DC,
1996) and approved by a local committee. Animals were maintained on
standard mouse chow at 22°C on a 12-h light-dark cycle with ad libitum access
to food and tap water. Food consumption and body weight were monitored
weekly in individualized animals. In all experiments, 12- to 18-week-old males
were used.
High-fat diet treatment. Mice were fed either standard diet (10% kcal fat) or
high-fat diet (45% kcal fat) (Research Diets, New Brunswick, NJ) for 9 weeks.
After the treatment, mice were killed for blood and tissue collection. The sera
were separated for leptin and insulin quantification with ELISA kits (R&D
Systems [Minneapolis, MN] and Millipore [Billerica, MA], respectively). Tis-
sues explants were weighed and used for adipocyte isolation, or frozen for
protein, RNA, or triglycerides extraction.
Body composition analysis. Total body fat was estimated by dual-energy
X-ray absorptiometry using a Hologic QDR 4500 scanner (Hologic, Waltham,
MA) as described previously (25).
Adipose tissue cellularity. Isolation of fat cells and calculation of adipocyte
volume and number in epididymal fat depots were performed as previously
described (26). Briefly, images of isolated adipocytes were acquired from a
light microscope fitted with a camera, and the average cellular volume was
estimated by measuring the diameter of at least 100 adipocytes per animal
using the software ImageJ (http://rsb.info.nih.gov/ij/). Fat cell number was
calculated by dividing the adipose tissue triglyceride content by the average
adipocyte lipid content, obtained by the multiplication of the average fat cell
volume by the triolein density (0.92).
Gene and protein expression. Please refer to the online appendix (available
at http://dx.doi.org/10.2337/db07-1508).
Energy expenditure. In vivo indirect open circuit calorimetry was per-
formed as previously described (26). Briefly, respiratory exchanges and
spontaneous activity signals of freely moving mice were computed at 10-s
intervals using a computer-assisted data acquisition program (ADDENFI
metabolic chamber prototype). Mice were housed individually in the meta-
bolic cages at 10:00 A.M. without food, and the postabsorptive resting energy
expenditure (basal metabolism) was measured between 4:00 and 6:00 P.M. At
6:00 P.M., we gave a 1-g meal of either control or high-fat diet to the mice and
computed the increase in energy expenditure in response to feeding (metab-
olism and respiratory quotient).
Leptin sensitivity. To determine leptin sensitivity, we administered recom-
binant mouse leptin (40 g  day1 mouse1 i.p.; R&D Systems) during 4 days
(at 5:00 P.M.) and evaluated food intake and/or weight loss. Food intake during
5 days before leptin injection was considered as the basal consumption
(100%). An independent group of fasted animals was killed 45 min after the
first leptin bolus for hypothalamus collection, protein extraction, and Western
blotting quantification of pSTAT3 and STAT3.
SSR240612 chronic administration. ALZET micro-osmotic pumps (Alza,
Palo Alto, CA), set to deliver for 28 days either SSR240612 (3 mg  kg1 body
wt  day1; Sanofi-Aventis, Paris, France) or vehicle (2% DMSO), were
subcutaneously implanted in anesthetized C56Bl/6 mice under sterile condi-
tions. Seven days after the implant, mice were submitted to high-fat diet for 3
weeks. Body weight and food intake were assessed weekly in the period of 1
month before and after the implant. At the end of the treatment, pumps were
checked for their contents, and animals with filled ones were not considered
in the data analysis.
Statistical analysis. All values were expressed as means  SE. Statistical
analyses were carried out using two-tailed Student’s unpaired t test to
compare two independent groups or ANOVA followed by Bonferroni’s test to
compare more than two. Significance was rejected at P  0.05.
RESULTS
B1
/ mice are lean. To assess possible contributions of
the kinin B1 receptor to the regulation of satiety and
adiposity in mice, we analyzed body weight, energy
intake, and adipose mass in standard or high-fat diet–
fed B1
/ and wild-type animals. Although no differ-
ences were found in the body weight (Fig. 1A) and
energy intake (Fig. 1B) between wild-type and B1
/
mice under control diet, a drastic reduction of fat mass
was observed in the knockout animals under this con-
dition (Fig. 1C and D). Lean mass, however, was in-
creased in these mice, accounting for their normal body
weight when compared to wild type (Fig. 1C). On the
other hand, under high-fat diet, B1
/ mice exhibited
impaired energy intake (Fig. 1B) and were remarkably
refractory to the effect of the diet on body weight gain
(Fig. 1A). In addition, total adiposity and fat accumula-
tion by adipocytes were dramatically reduced in B1
/
mice under both diets (Fig. 1E and F), whereas the
number of fat cells in the gonadal depots was only
decreased in B1
/ mice under standard diet (Fig. 1G).
Obesity is normally associated with insulin resistance
and glucose intolerance. Thus, we investigated these pa-
rameters in wild-type and B1
/ mice under standard or
high-fat diet. In agreement, B1
/ mice presented im-
proved glucose tolerance and reduced insulin levels in
both diets in comparison with the wild type (online
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appendix), confirming our previous data showing in-
creased insulin sensitivity in these mice (21).
Next, we measured serum leptin levels (Fig. 2A) and the
expression of leptin mRNA (Fig. 2B) and protein (Fig. 2C)
in the epididymal white adipose tissue of wild-type and
B1
/ mice. In all cases, we observed a significant de-
crease in leptin content in B1
/ mice when compared
with wild-type mice. Notably, high-fat diet did not lead to
an increase of leptin levels in B1
/ mice.
Taken together, these results demonstrate that B1
/
mice have reduced adiposity and are strongly resistant to
diet-induced hyperleptinemia and body weight gain.
Improved energy expenditure with spontaneous ac-
tivity and lipid oxidation in B1
/ mice under high-fat
diet. Analysis of feed efficiency (body weight gain/energy
consumed) (Fig. 3A) revealed that inhibition of weight
gain observed in B1
/ mice under high-fat diet could not
be totally explained by decreased energy intake (Fig. 1B).
Therefore, we quantified the components of total energy
expenditure under normal and high-fat feeding in B1
/
and wild-type mice. No differences in resting energy ex-
penditure, increase in energy expenditure in response to
feeding, or differences in respiratory quotient (respiratory
quotient, VCO2/VO2) in the postabsorptive state (4 h before
meal and 8–12 h after meal) were observed between B1
/
and wild-type mice (Table 1). Under standard diet, respi-
ratory quotient levels after feeding were 1.0 in both
groups, suggesting that de novo lipogenesis in response to
carbohydrate ingestion is occurring in these animals at a
similar extent. In contrast, under high-fat diet, B1
/ mice
exhibited a meal-induced increase in respiratory quotient
that lasted 4 h less than in wild-type mice (Fig. 3B and C),
indicating that postprandial inhibition of lipid oxidation is
significantly lower in these animals. In addition, B1
/
mice under high-fat regimen expended significantly more
energy with activity (46.6%, P 	 0.002; Table 1). To-
gether, these data suggest that B1
/ mice can resist
high-fat diet–induced weight gain in part due to increased
energy expenditure with spontaneous activity and de-
creased inhibition of lipid oxidation in response to a fat
meal.
Hypersensitivity to leptin in B1
/ mice. Together,
hypoleptinemia, protection against high-fat diet–induced
hyperleptinemia, elevated energy expenditure, and re-
duced food intake under high-fat diet suggest increased
leptin responsiveness in B1
/ mice. To test this hypothe-
sis, we administered exogenous leptin to B1
/ and wild-
type mice and quantified daily food intake and
phosphorylation of STAT3, a downstream component of
the Ob-Rb signaling pathway, in the hypothalamus of these
animals. A stronger inhibitory effect of exogenous leptin
on food intake in B1
/ mice was observed when com-
pared with wild-type mice (Fig. 4A). Furthermore, the
levels of phosphorylated STAT3 after leptin injection were
significantly higher in the hypothalamus of B1
/ in com-
parison with wild-type mice (Fig. 4B). In addition, we
measured the expression of Ob-Rb mRNA in hypothala-
mus of B1
/ and wild-type mice and found upregulation
of this transcript in B1
/ (Fig. 4C). Moreover, the expres-
sion of SOCS3, a potent inhibitor of the Ob-Rb signaling,
was decreased in hypothalamus of B1
/ mice (Fig. 4D).
These data suggest that Ob-Rb signaling is facilitated in
B1
/ mice, which could contribute to the inhibition of
food intake and enhanced energy expenditure in these
animals under high-fat diet. Another aspect of leptin
sensitivity, the passage of leptin through the blood-brain
barrier, was addressed in B1
/ and wild-type mice by
measuring brain accumulation of intravenously injected
[125I]-labeled leptin. Although B1
/ mice had a tendency
to an increased leptin passage to the brain, no significant
differences were observed in relation to the wild-type mice
(data not shown).
We also assessed kinin B1 receptor mRNA expression in
the hypothalamus of wild-type mice after 9 weeks of high-fat
B
o
d
y 
w
ei
g
h
t
(g
)
A
Time (weeks)
†
*
* * *
* *
* *
† †
†
†
† † †
WT Control
B1-/- Control
WT HFD
B1-/- HFD
20
25
30
35
40
45
0 2 4 6 8 10
B
E
n
er
g
y 
in
ta
ke
 
(k
C
al
/w
ee
k)
Time (weeks)
*†
WT Control
B1-/- Control
WT HFD
B1-/- HFD
70
80
90
100
110
120
130
0 2 4 6 8 10
†*
*
B1-/-
100 µm
E
WT
Control diet HFD
D
0
0.5
1
1.5
2
2.5
WT
B1-/-
E
p
id
id
ym
al
 f
at
(g
)
*
*
**
**
Control
Diet
HFD
G
WT
B1-/-
0
0.5
1
1.5
2
2.5
3
A
d
ip
o
cy
te
 n
u
m
b
er
 (
x1
0
6 )
**
*
Control
Diet
HFD
F
*
*
A
d
ip
o
cy
te
 v
o
lu
m
e 
(c
m
3 x
10
-6
)
*
Control
Diet
HFD
0
0.2
0.4
0.6
0.8
1
1.2
1.4
WT
B1-/-
C
Control
Diet
B
o
d
y 
co
m
p
o
si
ti
o
n
 (
g
) Fat mass
Lean mass
*
HFD
WT B1-/- WT B1-/-
0
10
20
30
40
50
*
†
†
FIG. 1. Reduced fat mass in B1
/ mice. Twelve-week-old wild-type and B1
/ mice were submitted to standard (control) or high-fat diet (HFD)
for 9 weeks and body weight (A), energy intake (B), total fat mass (C), epididymal fat weight (D), isolated adipocyte morphology (E), and average
adipocyte volume (F) and number (G) were measured. , wild type under control diet; , B1
/ under control diet; Œ, wild type under HFD; E,
B1
/ under HFD. Results are means  SE. A and B: *P < 0.05 B1
/ HFD versus wild-type HFD. †P < 0.05 wild-type control diet versus wild-type
HFD; n  11 per group. C: *P < 0.05 B1
/ fat mass versus wild-type fat mass. †P < 0.05 B1
/ lean mass versus wild-type lean mass; n  5 per
group.D, F, andG: *P< 0.05. **P< 0.01 between indicated groups; n 6 per group. Microscopy images are representative examples of six animals
per group.
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regimen. Interestingly, we found higher levels of this mRNA
in high-fat diet–fed mice, in comparison with animals under
standard diet (Fig. 4E). Taken together, these results indicate
that the kinin B1 receptor may participate in the mechanism
of leptin resistance in obesity.
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gain/energy consumed) was calculated during this period (n  11 per
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*P < 0.05; **P < 0.01 between indicated groups.
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Kinin B1 receptor deficiency does not protect ob/ob
mice from obesity. To estimate the importance of leptin
hypersensitivity to the phenotype of resistance to obesity
in B1
/mice, we generated mice lacking both B1 receptor
and leptin (ob/ob-B1
/). In comparison with ob/ob mice,
ob/ob-B1
/ had no differences in body weight (Fig. 5A)
and exhibited no significant morphological alterations,
except for mildly heavier heart and kidney (data not
shown). We also did not observe differences between the
ob/ob and the ob/ob-B1
/ mice on daily food ingestion
(Fig. 5B) and on some parameters of adiposity in these
animals, including epididymal fat content (Fig. 5C) and
adipocyte volume (Fig. 5D and E) and number (Fig. 5F).
These data suggest that leanness associated with kinin B1
receptor deficiency may be dependent on the leptin
signaling.
Leptin is more effective to promote weight loss in
ob/ob-B1
/ mice. Next, we performed daily injections of
exogenous leptin to ob/ob-B1
/ and ob/ob mice and mea-
sured food intake, body weight, and feed efficiency. Inter-
estingly, we found that the first dose of leptin was more
efficient to inhibit food intake (Fig. 6A) and to promote
weight loss (Fig. 6B) in ob/ob-B1
/ mice in comparison
with ob/ob. In addition, ob/ob-B1
/ presented a significant
reduction of feed efficiency on the first day of leptin
administration (Fig. 6C), indicating that weight loss in this
condition is not exclusively due to inhibition of food
intake. To corroborate these data, we quantified leptin-
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FIG. 4. Increased leptin sensitivity in B1
/ mice. A: Inhibition of food intake of wild-type and B1
/ mice under standard diet by administration
of exogenous murine leptin (40 g  day1  mouse1 i.p.). Values represent percent change of the basal food ingestion collected during 5 days
before leptin injections. , wild-type mice; , B1
/ mice. B: STAT3 phosphorylation in the hypothalamus of overnight fasted wild-type (f) and
B1
/ () mice, 45 min after intrapritoneal injection of 40 g leptin or saline. C and D: Expression of Ob-Rb mRNA and SOCS3 in the
hypothalamus of overnight fasted wild-type and B1
/ mice under standard diet was assessed by real-time PCR and Western blot, respectively. E:
B1 mRNA expression in the hypothalamus of C57Bl/6 mice after 9 weeks of control or high-fat diet (HFD). STAT3 and SOCS3 expression is
representative of two independent protein pools of five animals per group. Histograms below these panels represent the quantification of the
bands using the software ImageJ for optical density analysis. All other results show means  SE of at least five animals per group. Twelve- to
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TABLE 1
Components of the total energy expenditure in B1
/ mice
Control diet High-fat diet
Wild type B1
/ Wild type B1
/
Resting EE (kCal  day1  kg1) 2.33 0.14 2.70 0.31 3.26 0.23 3.16 0.08
Postabsorptive RQ 0.868 0.012 0.853 0.014 0.784 0.005* 0.780 0.006*
Food-induced increase in EE (kCal) 1.76 0.2 1.77 0.8 0.31 0.3* 0.45 0.4*
EE with activity (kCal  day1  kg1) 123.6 4.1 105.0 16.3 37.9 1.2* 55.7 5.5*†
Data are means  SE of Q5 animals per group. Twelve-week-old wild-type and B1
/ mice were submitted to standard diet (control) and
high-fat diet for 9 weeks. *P 	 0.05 high-fat diet vs. control diet. †P 	 0.05 wild-type vs. B1
/. EE, energy expenditure; RQ, respiratory
quotient.
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stimulated STAT3 phosphorylation in the hypothalamus of
ob/ob-B1
/ and ob/ob mice. As expected, ob/ob-B1
/
showed increased levels of phosphorylated STAT3 after
leptin induction (Fig. 6D). These results bring forth the
hypothesis that the kinin B1 receptor may play a role in
energy homeostasis through the modulation of leptin
responsiveness.
The kinin B1 receptor antagonist SSR240612 inhibits
high-fat diet–induced weight gain, energy intake, and
feed efficiency in mice. To validate our findings using
knockout models and to confirm the pathophysiological
function of the kinin B1 receptor in obesity, we pharma-
cologically blocked this receptor in mice for 28 days by
chronic administration of the nonpeptide orally active B1
receptor antagonist SSR240612 (3 mg  kg1 body wt 
day1) and measured body weight gain and food intake
weekly during this period. In the 1st week, mice were fed
with a standard diet and showed no significant differences
in body weight (Fig. 7A) and energy intake (Fig. 7B)
between the groups receiving SSR240612 or the vehicle.
However, after being submitted to a high-fat diet, mice
receiving SSR240612, in comparison with the control mice,
showed a clear inhibition in body weight gain (Fig. 7A) and
energy intake (Fig. 7B). In addition, feed efficiency under
high-fat diet was significantly decreased in mice treated
with SSR240612 (Fig. 7C). Thus, these data show ample
evidence to support the hypothesis that kinin B1 receptor
blockade protects mice from weight gain.
DISCUSSION
Although significant progress has been made in the
identification of genes contributing to metabolic dis-
eases, many pieces of the puzzle are still missing. Our
data indicate that one member of the kallikrein-kinin
system, the kinin B1 receptor, may be an important part
in this scenario because it seems to play a significant
role in the regulation of food intake and energy expen-
diture exerted by leptin. Before this study, however, few
relevant physiological roles had been attributed exclu-
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sively to the activation of the kinin B1 receptor. More-
over, in most physiological processes in which the
expression of B1 receptors was observed, the kinin B1
receptor was considered a secondary player, serving as
an alternative in case of B2 receptor deficiency (14,27).
However, recent results from our group showed that
kinin B1 receptor activation modulates leptin homeosta-
sis (24). In addition, here we present sufficient evidence
to support the idea that kinin B1 receptors are in fact
participating in essential metabolic processes.
The kinin B1 receptor, like many inflammatory mole-
cules, including tumor necrosis factor- (TNF-) (28) and
LPS (29), may act through redundant pathways to display
both its inflammatory and metabolic actions. Similarly,
leptin has inflammatory actions and strongly controls
energy homeostasis (6), mainly by regulating satiety and
potentiating many components of the total energy expen-
diture, including the energy expended with physical activ-
ity (8) and with fat oxidation (7,30). According to our data,
leptin may be a key mediator of the metabolic actions of
the kinin B1 receptor. Firstly, despite the gain of fat tissue
after the high-fat regimen, B1
/ mice are completely
protected against high-fat diet–induced hyperleptinemia,
suggesting that leptin is not correlated with adiposity
levels in these mice. Furthermore, ob/ob-B1
/ and ob/ob
mice are similarly obese, indicating that leptin may be
necessary for the kinin B1 receptor to affect food intake
and energy expenditure. Finally, B1 receptor deficiency
increases leptin responsiveness and exacerbates the ef-
fects of exogenous leptin on weight loss in ob/ob mice.
Although the precise mechanism underlying the interac-
tion between the kinin B1 receptor and the leptin signaling
pathway is still unclear, accumulating evidence showing
the presence of this receptor and other components of the
kallikrein-kinin system in the hypothalamus of rodents and
humans (23,31,32) lead us to the hypothesis that the
modulation of leptin sensitivity by the B1 receptor may
involve a central phenomenon. In agreement, we observed
more pronounced effects of exogenous leptin administra-
tion on food intake inhibition in B1
/ mice. These exper-
iments, based on previously described protocols (8,33,34),
reflect observations obtained from daily injections of
high doses of leptin and may therefore represent supra-
physiological effects. Nevertheless, increased central
leptin sensitivity in B1
/ mice is corroborated by
increased leptin-induced STAT3 phosphorylation, up-
regulation of Ob-Rb mRNA, and reduced levels of
SOCS3 under basal conditions in the hypothalamus of
these animals.
SOCS3 is a member of a family of cytokine-inducible
suppressors of cytokine signaling that particularly inhibits
leptin signal transduction (13). In mouse embryonic fibro-
blasts, TNF-–dependent activation of the nuclear fac-
tor-B (NF-B) is able to induce SOCS3 expression and,
consequently, elicit negative effects on STAT signaling
(35). As an inflammatory mediator, the kinin B1 receptor
can also activate NF-B (36). Therefore, a possible mech-
anism to explain the downregulation of SOCS3 in B1
/
mice would be a reduction of B1 receptor–induced NF-B
activity in Ob-Rb neurons. Moreover, B1 receptor defi-
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ciency could lead to an understimulation of the hypotha-
lamic cytokine signaling due to a decrease in cytokine
production. Studies have shown that kinins can induce
TNF- and interleukin (IL)-1 release from macrophages
(37) and IL-6 expression by astrocytes (38).
Obesity has also been linked to increased inflammation
and macrophage infiltration in the adipose tissue (39). It is
postulated that cytokines produced by the adipose tissue,
which include leptin, TNF-, and some ILs, are pivotal
factors in the control of metabolism. In previous studies,
B1 receptor deficiency has been associated with hypoalge-
sia and reduced inflammatory response (18,19). It was
demonstrated that the hypotensive effect of LPS was
blunted in B1
/ mice and the infiltration of polymorpho-
nuclear leukocytes into tissues. The contributions of the
kinin B1 receptor to the inflammatory status of the adipose
tissue are, however, not clear. Thus, future experiments
may be proposed to understand how the absence of B1
receptors in the adipose tissue could modulate inflamma-
tory mediators to participate in the phenotypes observed
in B1
/ mice.
On the other hand, the regulation of the energy balance
by kinin B1 receptor may not be related exclusively to
activation by kinins. Recently, Lai et al. (40) presented
strong evidence that kinins are not the only agonists that
bind to kinin receptors. They showed that the endogenous
opioid peptide dynorphin A promotes neuropathic pain
through the activation of both kinin B1 and B2 receptors. In
the early 80s, 3 years after dynorphins were identified as
opioid regulators of pain and stress responses, these
peptides were described as potent inducers of food intake
(41,42). However, in 2 decades, modest advances have
been made to provide a solid understanding of the mech-
anisms mediating the regulation of energy balance by
dynorphin. Nevertheless, evidence showing that dynor-
phin neurons in the arcuate nucleus are leptin responsive
(43) and that the effect of -opioid agonists on food intake
cannot be reproduced in ob/ob mice (44) indicates that
leptin may be required for this event to happen. Thus, we
speculate that dynorphin may act through the kinin B1
receptor to control food intake via modulation of the
leptin signaling.
In general, protection against obesity is a common
feature of mice with leptin hypersensitivity. SOCS3 gene
disruption in the brain, for instance, is able to increase
leptin sensitivity and promote resistance to high-fat diet–
induced weight gain and hyperleptinemia (33). Moreover,
the neuron-specific tyrosine phosphatase protein-tyrosine
phosphatase 1B (PTP1B) knockout mice are over-respon-
sive to the effects of exogenous leptin and show reduced
adiposity and elevated energy expenditure with activity
(34). Thus, targeting SOCS3 and targeting PTP1B are
currently considered attractive strategies to fight obesity
and diabetes.
Similarly, CB1 cannabinoid receptor knockout mice
(45,46) are more sensitive to intracerebroventricular
injections of leptin, have decreased body weight, and
are slightly hypophagic. In addition, they are resistant to
high-fat diet–induced weight gain due to an increase in
energy expenditure. Based on this animal model, re-
searchers evidenced a strong anti-obesity effect of the
CB1 receptor antagonist SR141716A (46), and currently,
under the name of rimonabant, this drug has been
considered the most efficient clinical therapy to treat
human obesity (47). Therefore, based on the presented
data, here we suggest the orally active kinin B1 receptor
antagonist SSR240612 as a potential tool to prevent
obesity. Although several experiments still must be
addressed to verify the clinical relevance of this drug,
we believe that our results and the grown body of
evidence showing limited expression of B1 receptors
under physiological conditions (14) may render the
kinin B1 receptor an interesting potential target to treat
obesity with low risks of severe side effects.
In summary, we have presented in this study consistent
data indicating that functional deficiency of the kinin B1
receptor can protect mice from obesity through a mecha-
nism that may involve leptin signaling.
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